Physician profile
Jack E Baron
NPI 1174543441
$1,803.51
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $893 · 2021: $124 · 2022: $67.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $242.95 | 2019-2020 | |
| Novo Nordisk INC | $151.10 | 2019-2020 | |
| Pfizer INC. | $136.47 | 2019 | |
| Amgen INC. | $127.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $108.38 | 2019 | |
| Abbvie INC. | $101.28 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $99.49 | 2019-2020 | |
| Genentech USA, INC. | $91.76 | 2019-2020 | |
| Esperion Therapeutics, INC. | $89.13 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $88.40 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.95 | 2019 | |
| Amarin Pharma, INC. | $65.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $61.90 | 2019-2020 | |
| Eisai INC. | $46.30 | 2020 | |
| Boston Scientific Corporation | $44.89 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $33.36 | 2019-2020 | |
| Corcept Therapeutics | $31.81 | 2020 | |
| Antares Pharma, INC. | $31.23 | 2020-2021 | |
| Abbott Laboratories | $21.32 | 2022 | |
| Optinose US, INC. | $19.74 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.22 | 2020 | |
| Astellas Pharma US INC | $19.15 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.64 | 2019 | |
| Ge Healthcare | $16.30 | 2020 | |
| Ibsa Pharma INC. | $14.94 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.06 | 2021 | |
| Nevro Corp. | $12.54 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.29 | 2019 | |
| Radius Health, INC. | $11.27 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.